APX-115 (free base)
CAS No. : 1270084-92-8
(Synonyms: Ewha-18278 (free base); Isuzinaxib (free base))
| Size | Price | Stock |
|---|---|---|
| 5mg | $120 | In-stock |
| 10mg | $200 | In-stock |
| 25mg | $420 | In-stock |
| 50mg | $680 | In-stock |
| 100mg | $1100 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-120801A |
| M.Wt: | 279.34 |
| Formula: | C17H17N3O |
| Purity: | >98 % |
| Solubility: | DMSO : 250 mg/mL (ultrasonic) |
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury[1].
IC50 & Target:Ki: 1.08 μM (Nox1), 0.57 μM (Nox2) and 0.63 μM (Nox4)[1]
In Vitro: APX-115 free base (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression in the mouse podocyte cell line[2].
In the kidney, APX-115 free base attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes[2].
In Vivo: APX-115 free base (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[2].
APX-115 free base treatment decreases the urinary excretion of albumin and plasma creatinine levels[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- APX-115 (free base)
- Cat. No.:
- HY-120801A
- Quantity:
Your information is safe with us.